Novel anticoagulants given to 60% of newly diagnosed AF patients

"These findings point to the need to conduct ongoing surveillance of the adoption of new agents into clinical practice, as well as the need for robust, real-world comparative-effectiveness analyses of these medications, to enable patients and providers to make informed decisions about their relative benefit, safety, and cost-effectiveness," Dr. Desai and his associates said.

This study was funded by an unrestricted research grant from CVS Caremark. Dr. Desai’s associates reported ties to CVS Caremark and Aetna.